B4GALT family mediates the multidrug resistance of human leukemia cells by regulating the hedgehog pathway and the expression of p-glycoprotein and multidrug resistance-associated protein 1 by Zhou, Humin et al.
OPEN
B4GALT family mediates the multidrug resistance of
human leukemia cells by regulating the hedgehog
pathway and the expression of p-glycoprotein and
multidrug resistance-associated protein 1
H Zhou1,2, H Ma1, W Wei1, D Ji3, X Song4, J Sun4, J Zhang*,5 and L Jia*,1
b-1, 4-Galactosyltransferase gene (B4GALT) family consists of seven members, which encode corresponding enzymes known
as type II membrane-bound glycoproteins. These enzymes catalyze the biosynthesis of different glycoconjugates and saccharide
structures, and have been recognized to be involved in various diseases. In this study, we sought to determine the expressional
profiles of B4GALT family in four pairs of parental and chemoresistant human leukemia cell lines and in bone marrow
mononuclear cells (BMMC) of leukemia patients with multidrug resistance (MDR). The results revealed that B4GALT1 and
B4GALT5 were highly expressed in four MDR cells and patients, altered levels of B4GALT1 and B4GALT5 were responsible for
changed drug-resistant phenotype of HL60 and HL60/adriamycin-resistant cells. Further data showed that manipulation of these
two gene expression led to increased or decreased activity of hedgehog (Hh) signaling and proportionally mutative expression of
p-glycoprotein (P-gp) and MDR-associated protein 1 (MRP1) that are both known to be related to MDR. Thus, we propose that
B4GALT1 and B4GALT5, two members of B4GALT gene family, are involved in the development of MDR of human leukemia cells,
probably by regulating the activity of Hh signaling and the expression of P-gp and MRP1.
Cell Death and Disease (2013) 4, e654; doi:10.1038/cddis.2013.186; published online 6 June 2013
Subject Category: Cancer
Glycosyltransferases (GTs) catalyze the transfer of sugar
moieties from activated donor molecules to specific acceptor
molecules that determines the biosynthesis of glycans. In
recent years, glycosylation changes in disease symptoms and
development have been explored intensively.1 It has shown
that oligosaccharide expression may be associated with
carcinogenesis, metastasis and development of chemoresis-
tance of malignant cells.2–4 Although the alterations of glycan
structures are observed in drug resistance leukemia cells,5,6
there is limited report about the effects of GTs and
corresponding glycogenes in the development of leukemia
drug resistance.
B4GalT gene family encodes a set of type II transmem-
brane glycoproteins that transfer galactose in a b-1, 4 linkage
to similar acceptor sugars. There are seven members of the
b-1, 4-galactosyltransferase (b1, 4-Gal-T1) family, all of which
are expressed in a tissue-specific manner.7 As a house
keeping enzyme, b1, 4-Gal-T1 is thought to be the key
enzyme to have important roles in many biological events,
including morphogenesis, mammalian fertilization, brain
development, cellular adhesion, and so on.8-11Abnormal
expression of b1, 4-Gal-T has been shown to be implicated
in a number of diseases12–15, and levels of cell surface b1,
4-Gal-T could be influenced by many factors. Literatures show
that estrogen and arachidonic acid promote proliferation and
cell adhesion of human breast cancer cells by inducing b1,
4-Gal-T1 expression.13,16 In embryonic stem cells, b1, 4-Gal-
T1 expression is regulated by a novel ubiquitin-conjugating
enzyme accounting for intercellular adhesion and embryonic
development.17 B4GALT is also identified as an apoptosis-
related gene in some cancer cells and contributes to the
activation of signal transduction pathways.18
The hedgehog (Hh) signaling pathway consists of a series
of proteins that are necessary for embryogenesis, cell
development and proliferation. To date, tremendous evidence
indicates that Hh signaling activation might be associated with
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a wide variety of human tumors. The key signal molecules of
Hh network are recognized as oncogenes, such as smooth-
ened (Smo), sonic hedgehog (Shh) and glioma-associated
oncogene (Gli-1).19 Furthermore, several reports indicate
that aberrant activation of Hh pathway leads to the survival
and drug resistance of different types of human cancer
cells.20 Specific inhibition of the Hh pathway may therefore be
an effective therapeutic strategy for overcoming treatment
resistance of malignant tumors, for example, upregulation of
Gli-1 is correlated with glioma recurrence after chemother-
apy, and blocking the Hh pathway activity elevates
chemosensitivity of glioma cells.21 In leukemic cells, che-
moresistance is shown to be maintained by Hh signaling
activation, and could be reversed by cyclopamine, a known
Hh antagonist.22
A number of studies have focused on the mechanisms of
acquired multidrug resistance (MDR) of leukemia cells.
Among these, permeability glycoprotein, also known as
ATP-binding cassette (ABC) subfamily B member 1, is a
contributing factor for MDR. Xenobiotic compounds are
transported outside the cell by this protein depending on
ATP. Under physiological conditions, p-glycoprotein (P-gp)
protects the body against harmful substances through
inhibiting drugs reabsorption and keeping the integrity of the
blood–brain barrier. In cancer stem cells with MDR, P-gp is
responsible for the medicines clearance and promotes the
development of chemoresistance.23
MDR-associated protein 1 (MRP1) is another member of
ABC transporters, which transports anticancer drugs across
cellular membranes and reduces drug accumulation in the
cells. MRP1 is closely involved in MDR in several types of
cancer.24 Elevated level of MRP1 is often found in various
malignant cells before drug treatment.
We previously identified that B4GALT1 gene enhanced the
activity of Hh signaling and promoted MDR in K562/
adriamycin-resistant (ADR) cell line.25 In current study, we
established the expressional profiles of B4GALT gene family
in four pairs of parental and chemoresistant human leukemia
cell lines and in BMMC of leukemia patients with MDR.
Overexpression of B4GALT1 and B4GALT5 had been
observed in all these MDR cells and cases. On the basis of
these findings, we further elucidated the possible mechan-
isms of action of these two genes in MDR.
Results
B4GALT1 and B4GALT5 are upregulated in four ADR
leukemia cell lines. Here, we performed real-time PCR and
western blotting in order to search for abnormally expressed
genes and proteins of B4GALT family in four ADR cell lines.
Remarkable increases of B4GALT1 and B4GALT5 were
observed in four drug-resistant leukemia cells at both gene
and protein levels compared with those of four drug-sensitive
parental cell lines. No significant changes of the rest
members of B4GALT family were shown between parent
cell lines and their ADR cells. B4GALT6 gene was absent in
HL/60, NB4, U937 cells and their ADR sublines, while
B4GALT4 and B4GALT7 were undetectable only in U937
and U937/ADR cell lines (Figures 1a–h).
Suppression of B4GALT1 or B4GALT5 gene enhances
chemosensitivity of HL60/ADR cells in vitro and
in vivo. To investigate the impacts of B4GALT1 and
B4GALT5 on drug resistance of leukemia cells, HL60/ADR
cells were treated with B4GALT1 or B4GALT5 shRNA,
respectively. As shown in Figures 2a–d, the expression
levels of B4GALT1 and B4GALT5 were significantly reduced
in HL60/ADR-shRNA transfectants compared with control
transfectants.
After B4GALT1 or B4GALT5 shRNA transfection, the ability
of adriamycin, paclitaxel and vincristine to inhibit the growth of
HL60/ADR was evaluated by MTS assay. The results showed
that IC50 values were significantly decreased in HL60/ADR-
B4GALT1 shRNA cells group compared with the control,
suggesting that cell proliferation was inhibited by therapeutic
drug when HL/60 cells were treated with B4GALT1 shRNA.
Similar results were obtained with HL60/ADR-B4GALT5
shRNA cells group, chemosensitivity was remarkably
restored when B4GALT5 gene was suppressed (Figures 2e
and f).
To investigate the effect of knockdown of B4GALT1 or
B4GALT5 gene on chemosensitivity of leukemian cells, we
used nude mice bearing HL60/ADR, HL60/ADR-B4GALT1
shRNA and HL60/ADR-B4GALT5 shRNA xenografts to
analyze the differences of tumor volumes when therapeutic
drugs were administrated. In HL60/ADR-control shRNA
group, there was no significant difference in tumor volumes
between the mice groups with and without drug treatment, but
in HL60//ADR-B4GALT1 shRNA group, tumor volumes were
found to decrease significantly with drug treatment in
comparison with that of the mice group without drug
administration (Figure 2g). The same tendency was also
seen in HL60//ADR-B4GALT5 shRNA group (Figure 2h). After
the measurements of the tumor volumes, the tumors were
sectioned for immunohistochemical (IHC) staining analysis of
B4GALT1 and B4GALT5 expression patterns, the expression
of these two genes were reduced in the mice group with
shRNA treatment compared with untreated group or control
group (Figures 2i and j). These results demonstrated that
B4GALT1 and B4GALT5 genes were associated with the
drug-resistant phenotype of HL60/ADR.
Upregulation of B4GALT1 or B4GALT5 gene results in
acquirement of drug resistance of HL60 cells in vitro and
in vivo. After verifying the effect of B4GALT1 and B4GALT5
gene suppression on tumor cell chemosensitivity, we
transfected HL60 cells with B4GALT1 or B4GALT5 expres-
sion vector to determine the effect of overexpression of these
two genes on chemoresistance of HL60 cells. Notably,
increased levels of mRNA and protein of B4GALT1 and
B4GALT5 were detected in B4GALT1 and B4GALT5
transfectants (Figures 3a–d). MTS assay revealed that IC50
values of three drugs were significantly higher in HL60/
B4GALT1 and HL60/B4GALT5 cells than those in HL60
cells, suggesting a positive correlation between the two gene
expression and chemoresistance of leukemia cells (Figures
3e and f).
Nude mice were inoculated with tumor cells HL60, HL60/
mock, HL60/B4GALT1 and HL60/B4GALT5. Tumor volumes
were measured and compared between the groups with or
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without adriamycin treatment. In the group of mice bearing
HL60 tumors, tumor volumes with adriamycin treatment were
lower than those without. In the group of mice bearing HL60/
B4GALT1 or B4GALT5 tumors, tumor volumes increased
obviously even after adriamycin treatment (Figures 3g and h).
High expression of B4GALT1 and B4GALT5 in tumors cells of
HL60/B4GALT1 and HL60/B4GALT5 were illustrated by IHC
staining, as shown in Figures 3i and j. Therefore, upregulation
of B4GALT1 or B4GALT5 gene in HL60 cells led to raised
resistance to chemotherapy.
Downregulation of B4GALT1 or B4GALT5 inhibits the
activity of Hh signaling pathway and expression levels
of P-gp and MRP1. Here, we assessed the activity of the Hh
signaling by treatment of HL60/ADR cells with B4GALT1 or
B4GALT5 shRNA. The key molecules of Hh signaling,
Figure 1 B4GALT1 and B4GALT5 are upregulated at both mRNA and protein levels in four chemoresistant human leukemia cell lines. (a–d) The mRNA levels of B4GALT
gene family were detected by real-time PCR. Four ADR cells expressed higher levels of B4GALT1 and T5 mRNA than their parental cell types (*Po0.05). B4GALT6 gene was
not detectable in HL/60, NB4, U937 cells and their ADR sublines, while B4GALT4 and B4GALT7 were absent in U937 and U937/ADR cell lines. (e–h) By western blot,
b1, 4-Gal-T1 and T5 proteins were found to be highly expressed in four ADR cells compared with those of parental cells (*Po0.05), expressions of the rest enzymes of b1, 4-
Gal-T family were also consistent with mRNA levels
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Figure 2 Either B4GALT1 or B4GALT5 silencing facilitates HL60/ADR cells sensitive to therapeutic drugs. (a and b) B4GALT1 and B4GALT5 transcripts were decreased
apparently in HL60/ADR cells by shRNA treatment. (c and d) After shRNA transfection, distinct reduction of B4GALT1 or B4GALT5 was observed at protein levels by western
blot analysis. (e and f) In vitro MTS assay revealed that IC50 values of three drugs were decreased with the inhibition of B4GALT1 or B4GALT5 in HL60/ADR cells. (g and h)
When exposed to adriamycin, the tumor volume of nude mice bearing HL60/ADR-B4GALT1 shRNA or HL60/ADR-B4GALT5 shRNA xenograft was significantly diminished.
(i and j) Downregulation of B4GALT1 or T5 was also shown by IHC staining in xenograft tumors derived from HL60/ADR-B4GALT1 shRNA or HL60/ADR-B4GALT5 shRNA
cells ( 400). For a–f, i and j, asterisk denotes significant reduction from the groups without an asterisk (Po0.05), for g and h, *Po0.05
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Figure 3 Overexpression of B4GALT1 or B4GALT5 mediates the acquirement of MDR in HL60 cells. After full-length sequences transfection, both B4GALT1, T5 mRNAs
(a and b) and proteins (c and d) were increased notably in HL60 cells by real-time PCR and western blot. (e and f) MTS assay showed that elevated levels of B4GALT1, T5
made HL60 cells resistant to adriamycin, paclitaxel and vincristine in vitro. (g and h) The tumor volume was not distinctly reduced with adriamycin injection in nude mice
bearing HL60/B4GALT1 or HL60/B4GALT5 tumor. (i and j) IHC staining showed an enhanced expression of B4GALT1 or T5 in tumor samples generated from HL60 cells with
shRNA treatment. For a–f, i and j, asterisk indicates significant increase from the groups without an asterisk (Po0.05), for g and h, *Po0.05
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transcripts and proteins, were significantly reduced with
shRNA transfection, revealed by real-time PCR (Figures 4a
and b), western blotting (Figures 4c and d) and IHC staining
(Figures 4e and f and Supplementary Figure 1). P-gp and
MRP1 are the recognized molecules involved in the devel-
opment of MDR, we therefore examined whether gene
manipulation of B4GALT1 or B4GALT5 could influence the
expression of P-gp and MRP1. Lower expression levels of
Figure 4 Knockdown of B4GALT1 or B4GALT5 leads to Hh signaling suppression and P-gp, MRP1 downregulation. Expressions of Shh, Smo and GLI-1, the main
molecules of Hh pathway, were repressed at mRNA levels with B4GALT1, T5 shRNA transfection in HL60/ADR cells (a and b). The reduced protein levels of sonic Hh
signaling molecules were determined by western blot (c and d) and IHC staining (e and f). Decreased expressions of P-gp and MRP1 were examined by flow cytometry
analysis in B4GALT1, T5-shRNA-treated HL60/ADR cells (g and h). Asterisk indicates significant difference from the groups without an asterisk (Po0.05)
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P-gp and MRP1 were detected in HL60/ADR-B4GALT1
shRNA cells and HL60/ADR-B4GALT5 shRNA cells com-
pared with those in control cells by flow cytometric analysis
(Figures 4g and h).
Elevation of B4GALT1 or B4GALT5 gene expression
activates Hh pathway and promotes expression levels of
P-gp and MRP1. By contrast, overexpression of B4GALT1
or B4GALT5 in HL60 cells enhanced mRNAs and proteins
expression of Smo, Shh and GLI-1, as illustrated in Figures
5a–f and Supplementary Figure 2. Moreover, HL60 cells
expressed higher levels of P-gp and MRP1 with B4GALT1 or
B4GALT5 overexpression (Figures 5g and h). Thus, the
results may reveal an additional drug resistance mechanism
of B4GALT1 or B4GALT5 in MDR of leukemia cells.
Chemosensitivity of HL60/ADR cells is restored in
response to inhibiting Hh signaling activity. The effect
of Hh signaling activity on chemoresistance of HL60/ADR
cells was investigated by pharmacological inhibition of the Hh
pathway. In Figures 6a, b and e, HL60/ADR cells with
cyclopamine treatment showed significantly decreased
mRNA and protein levels of the main signal molecules of
Hh pathway. By methyl thiazolyl tetrazolium assay in vitro,
we observed the inhibition of Hh pathway caused HL60/ADR
cells sensitive to chemotherapy (Figure 6c), similar results
were also obtained by in vivo chemosensitivity analysis,
reduced tumor volumes were observed in mice group
bearing HL60/ADR tumors with impaired Hh signaling
(Figure 6d).
Furthermore, flow cytometric analysis was performed to
explore whether suppression of Hh signaling activity could
influence the proteins expression of P-gp and MRP1. Low
levels of P-gp and MRP1 were present in HL60/ADR cells
with cyclopamine treatment (Figure 6f). These data impli-
cated a role of Hh signaling in regulating P-gp and MRP1
expression and modulating the chemoresistance of HL60/
ADR cells.
Increased expression levels of B4GALT1 and B4GALT5
are detected in most AML and CML cases with
chemoresistance. To determine the expressions of MDR-
related marker and B4GALT1–B4GALT7 of the BMMC
samples from acute myeloid leukemia (AML) and chronic
myeloid leukemia (CML) patients, flow cytometry assay and
real-time PCR were carried out by using FITC-monoclonal
antibodies against P-gp, MRP1 and B4GALT1–B4GALT7.
Elevated mean fluorescence intensity of P-gp and MRP1 was
observed in 37 of 71 CML patients and 29 of 75 AML
patients. Then patients were divided into four groups: CML
without MDR, CML/MDR, AML without MDR and AML/MDR.
Each gene expression of B4GALT family of patient with MDR
was compared with that of patient without MDR to obtain
expression ratio. The value of each gene expression Z2 was
recognized to be significant. Data from 66 MDR patients
were summarized in Table 1. Higher levels of B4GALT1 and
B4GALT5 were found in chemoresistant leukemia samples,
but expression levels of the other members of B4GALT
family showed no difference between drug-resistant group
and chemosensitive group. According to these results, the
involvement of B4GALT1 and B4GALT5 overexpressions in
drug resistance of leukemia cells was further confirmed.
Discussion
As a global issue of increasing concern, MDR leads to
inadequate treatment and poor prognosis of leukemia
patients. For decades, some progress has been gained on
the mechanisms of MDR. Interestingly, our previous work has
implied B4GALT1, a kind of glycogene, acts as a MDR
mediator of human leukemia K562 cell line. Here, we carried
on the studies in order to investigate the association between
the B4GALT family and MDR of human leukemia cells.
Among seven members of B4GALT family, B4GALT1 is the
first gene to be cloned and characterized, and is identified as a
potential biomarker in malignancies.26,27 B4GALT2 and
B4GALT3 gene products catalyze the synthesis of N-linked
oligosaccharides in many glycoproteins and specific glycoli-
pids. Overexpression of B4GALT2 is proved to induce
apoptosis in Hela cells.28 Unlike b1, 4-Gal-T1, T2 and T3,
b1, 4-Gal-T4 has exclusive specificity for the acceptor sugars,
and does not catalyze the transfer of galactose to asialo-
agactotransferrin, asialo-agalacto-fetuin or ovalbumin. It has
been reported that highly expression of B4GALT4 is linked to
colorectal cancer metastasis and poor prognosis.29 b1, 4-Gal-
T5 participates in the formation of both N-linked oligosacchar-
ides and the various glycolipids. This enzyme could lead to
high galactosylation on cell surfaces, and has been proved to
be involved in the malignant phenotype of astrocytoma
and glioma, indicating a possible role in tumorigenesis.30,31
b1, 4-Gal-T6 catalyzes the biosynthesis of glycosphingolipids
in UDP-dependent manner using magnesium or zinc. So far,
there are few reports of the correlation of B4GALT6 to the
different diseases. b1, 4-Gal-T7 regulates the synthesis of
glycosaminoglycans and has roles in several pathophysiolo-
gical events,32 for example, a missense mutation in the
B4GALT7 gene is related to the Ehlers–Danlos syndrome
progeroid type.33
In current study, B4GALT1, T2, T3 and T5 transcripts and
proteins expressed constitutively in the four pairs of human
leukemia cell lines and in the tumor cells of leukemia patients.
B4GALT6 was not detectable in three pairs of cell lines except
K562 and K562/ADR cells, while nonexistence of B4GALT4
and B4GALT7 was only found in U937 and U937/ADR cell
line. All MDR cells and sample cells from patients with MDR
were characterized by elevated levels of B4GALT1 and
B4GALT5 compared with those of cells without MDR. These
two genes are well known for their key roles in the process of
proliferation, invasion and apoptosis of cancer cells. Our data
also showed evidence that abnormal expression of B4GALT1
and B4GALT5 has an impact on the development of multidrug
resistance, another malignant behavior of tumor cells.
Although B4GALT4 has been recognized involving in cancer
metastatic processes, we do not find a significant difference of
B4GALT4 expression between the cell groups with or without
MDR. After all, occurrence and development of tumors is a
complex multistep process different from MDR.
Glycosylation, occurring to most of the human proteins after
transcription, has important roles in the structural and
functional changing of protein. Glycan chains are essential
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in maintaining the normal physiological function of cells and
glycosylation alterations that have been studied intensively in
the tumor biology field so as to better understand how
diseases develop. It is well demonstrated that malignant cells
and normal cells differ significantly in the characteristic
changes of glycans and glycoconjugates.34–37 Biosynthesis
of glycans depends on GTs, the largest and most diverse
enzyme groups. As upstream regulators of glycoproteins,
Figure 5 Upregulation of B4GALT1 or B4GALT5 activates Hh pathway and elevates the expressions of P-gp, MRP1. Shh, Smo and GLI-1 transcripts and proteins were
proved to be enhanced in full-length B4GALT1 or B4GALT5-treated HL60 cells by real-time PCR (a and b), western blot (c and d) and IHC staining analysis (e and f),
respectively. Flow cytometry analysis revealed a higher coexpression of P-gp and MRP1 in HL60 cells with B4GALT1 or B4GALT5 transfection (g and h). Asterisk suggests
significant difference from the groups without an asterisk (Po0.05)
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Figure 6 Inhibition of Hh pathway by cyclopamine restrains coexpression of P-gp and MRP1, and promotes HL60/ADR cells sensitive to chemotherapy. Using real-time
PCR (a), western blot (b), and IHC staining analysis (e) downregulated Shh, Smo and GLI-1 transcripts and proteins were detected in cyclopamine-treated HL60/ADR cells.
Cyclopamine treatment also alleviated chemoresistance of HL60/ADR cells, revealed by in vitro (c) and in vivo (d) susceptibility test. Simultaneously, flow cytometry analysis
showed that suppression of Hh signaling resulted in reduced levels of P-gp and MRP1 (f). For a–c, e and f, asterisk indicates significant increase from the groups without an
asterisk (Po0.05), for d, *Po0.05 versus HL60/ADR-tomatidine cells and HL60/ADR-cyclopamine cells without adriamycin treatment
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GTs often exhibited abnormal activity in tumors, also in the
development of drug-resistance process.38 In this study, the
effects of B4GALT1 and B4GALT5 on MDR in HL60/ADR cell
line were confirmed by in vitro and in vivo drug susceptibility
analysis. We established two transfectants with stable
inhibition of B4GALT1 or B4GALT5 gene using RNAi
approach. Increased sensitivity of HL60/ADR cells to anti-
leukemia drugs was found with both B4GALT1 and B4GALT5
shRNA treatment. Conversely, in HL60 cells with the over-
expression of the two genes, acquirement of MDR was
observed. On the basis of this result, we propose that
B4GALT1 and B4GALT5 might function as critical genes
involving in MDR.
The Hh signaling is one of the most examined signal
pathways and participates in embryonic development, cell
proliferation, carcinogenesis, apoptosis and acquirement of
drug resistance.39–42 Previously, we have revealed that
B4GALT1 functioned as a modulator of Hh pathway in K562/
ADR cell line. Here, B4GALT5 also exhibited the similar effect
on the activity of Hh pathway in HL60/ADR cells, and blockage
of Hh pathway by cyclopamine alleviated chemoresistance of
HL60/ADR cells. These findings suggest both B4GALT1 and
B4GALT5 could promote the development of MDR probably
through regulating the Hh signaling pathway, where the main
molecules are all glycoproteins. Further analysis would be
necessary to estimate the glycosylation changes in drug-
resistant leukemia cells compared with drug-sensitive cells.
It has been reported that the Hh signaling enhances drug
efflux by ABC transporters in order to maintain MDR of tumor
cells.43 ABC transporters are a superfamily of transmembrane
proteins that transport a wide variety of substrates across cell
membranes. They are found on the surface of normal cells
and various cancer cells where they have crucial roles in the
development of MDR. P-gp and MRP1, two main members of
ABC transporters, are frequently used as markers to screen
MDR patients clinically. We found that the levels of P-gp and
MRP1, had a positive relationship with the expression of
B4GALT1, B4GALT5 and the activity of Hh signaling in HL60
and HL60/ADR cell lines. As B4GALT1 and B4GALT5 were
observed as regulatory genes on the activity of Hh signaling,
we assumed that B4GALT1 and B4GALT5 might elevate the
expression of P-gp and MRP1 through Hh pathway, thereby
promoting MDR of leukemia cells.
In conclusion, our data demonstrated that overexpression
of both B4GALT1 and B4GALT5 could activate the Hh
signaling and increase the levels of P-gp and MRP1, thus
reduce the efficacy of chemotherapy for leukemia cells.
Seeking for agents that simultaneously inhibit b1, 4-Gal-T1
and b1, 4-Gal-T5 might be a promising strategy for over-
coming MDR of leukemia patients.
Materials and Methods
Cell lines and culture conditions. Four human cell lines, including a
chronic myelogenous leukemia cell line (K562), an acute myelogenous leukemia
cell line (HL60), an acute promyelocytic leukemia cell line (NB4) and a leukemic
monocytic lymphoma cell line (U937) were purchased from the China Center for
Type Culture Collection (CCTCC, Wuhan, China). All cell lines were cultured in RPMI
1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-
inactivated fetal bovine serum (Gibco) and 1% penicillin–streptomycin (Gibco) at 37 1C
in 5% CO2. We established four ADR sublines namely K562/ADR, HL60/ADR, NB4/
ADR and U937/ADR from corresponding parental cell lines by stepwise exposures of
cells to increasing concentrations of adriamycin from 1mg/ml up to 5mg/ml for 2
months. All ADR sublines could grow in the presence of chemotherapeutic agents,
including adriamycin, paclitaxel and vincristine. One week before subsequent
treatments, ADR cells were maintained in complete medium without adriamycin and
cells with 490% viability were used for further studies.
Samples of patients. Seventy-one cases of CML patients and 75 cases of
AML patients were included in this study after obtaining informed consent. The
diagnosis of CML and AML was based on morphology, immunology, molecular
and cytogenetic classification. All patients were treated in the First Affiliated
Hospital of Dalian Medical University between March 2009 and May 2011. Bone
marrow samples were collected at diagnosis and before treatment. Bone marrow
mononuclear cells (BMMCs) were isolated by Ficoll-Hypaque density gradient
centrifugation (Sigma-Aldrich, INC. St. Louis, MO, USA) and were cultured in
plastic dishes to remove adherent cells at 37 1C for 24 h. Freshly separated non-
adherent cells were maintained in modified Dulbecco’s medium containing 10%
fetal bovine serum, 10 mM b-mercaptoethanol, 2 mM L-glutamine, 50 ng/ml
human stem cell factor, 10 ng/ml human interleukin-3 and 10 ng/ml human
interleukin-6. The expressions of P-gp and MRP1 were measured by flow
cytometric assays to determine the resistant phenotype of patients. B4GALT1-7
levels of all patients were determined by real-time PCR.
Real-time PCR analysis. Real-time PCR was used to analyze gene
expression. Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Valencia,
CA, USA), and cDNA was synthesized using QuantiTect Reverse Transcription Kit
(Qiagen), according to the manufacturer’s protocol. Real-time PCR was carried out
on an ABI Prism 7500 fast real-time PCR system (Applied Biosystems, Foster
City, CA, USA) using QuantiTect SYBR Green PCR Kit (Qiagen). The primer pairs
for PCR are listed in Table 2. Ratios of each gene and GAPDH gene expression
levels were determined by subtracting the threshold cycle number (Ct) of the
target gene from the Ct of GAPDH. The relative expression level of each gene was
normalized to that of respective GAPDH.
Western blot analysis. Cells (1 106) were collected and lysed by adding
1 ml of 2 concentrated electrophoresis sample buffer (125 mM Tris-HCl, pH 6.8,
5% glycerol, 2% SDS, 1% b-mercaptoethanol) to each Eppendorf tube. Protein
concentrations were determined by a Micro BCA Protein Assay kit (Pierce,
Rockford, IL, USA) according to the manufacturer’s protocol. Fifty micrograms of
total protein were resolved by SDS-PAGE (10%) gel and then blotted onto a
polyvinylidene difluoride membrane. After being blocked for 2 h with phosphate-
buffered saline containing 0.1% Tween-20 and 5% powdered skim milk, the blots
were incubated, respectively, overnight at 4 1C with rabbit anti human
B4GALT1(Abcam, Cambridge, UK; 1 : 250 dilution), B4GALT2 (Abcam; 1 : 100
dilution), B4GALT3, 4, 5, 7 (Abcam; 1 : 500 dilution), B4GALT6 (Abcam; 1 : 200
dilution), Shh (Abcam; 1 : 2000 dilution), Smo (Abcam; 1 : 100 dilution) and GLI-1
Table 1 Expressional profiles of B4GALT gene family and P-gp, MRP1 in AML
and CML patients with MDR
Cases AML no. (%) CML no. (%)
Age
o60 26 (89.7) 16 (43.2)
Z60 3 (10.3) 21 (56.8)
Gender
Male 17 (58.6) 23 (62.2)
Female 12 (41.4) 14 (37.8)
ZTwofold higher levels versus patients without MDR
B4GALT1 19 (65.5)* 25 (67.6)*
B4GALT2 2 (6.9) 3 (8.1)
B4GALT3 0 (0) 4 (10.8)
B4GALT4 0 (0) 0 (0)
B4GALT5 16 (55.2)* 22 (59.5)*
B4GALT6 0 (0) 0 (0)
B4GALT7 0 (0) 0 (0)
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia;
MDR, multidrug resistance
*Po0.05 versus patients without MDR
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antibodies (Abcam; 1 : 40 dilution), and then incubated with secondary antibody
anti-rabbit-HRP (GE Healthcare UK Ltd, Little Chalf-ont, UK; 1 : 10 000 diluted).
GAPDH antibody (Santa Cruz Biotech, Santa Cruz, CA, USA; 1 : 1000 dilution)
was used as internal marker for control. All bands intensities were evaluated using
ECL Western blotting kit (Amersham Biosciences, Buckinghamshire, UK) and
were normalized to those of GAPDH.
Deregulation of B4GALT1 or B4GALT5 in HL60/ADR cells by
RNAi. Transfection was performed in a 12-well plate at B 50% confluent
cultures. HL60/ADR cells were maintained in 1 ml of complete medium with 5mg/
ml Polybrene (sc-134220, Santa Cruz Biotech) per well and were treated with
0.4mM B4GALT1 or T5-specific shRNA lentiviral particles (sc-40616-V and sc-
72405-V, Santa Cruz Biotech) overnight, three control wells were transduced with
control shRNA lentiviral particles (sc-108080, Santa Cruz Biotech). Then medium
in each well was replaced with 1 ml of complete medium (without Polybrene) and
cells were diluted to 1 : 3 for selecting stable clones expressing the shRNA by
5mg/ml puromycin dihydrochloride (sc-108071, Santa Cruz Biotech). The
transfection efficiency was about 80% and cell viability was 90% by trypan blue
dye exclusion assay. Four weeks later, several resistant colonies were picked and
expanded for further study.
Overexpression of B4GALT1 or B4GALT5 in HL60 cells. The
human B4GALT1, B4GALT5 and Shh coding sequences were obtained from
TaKaRa company (Dalian, China) and were inserted into the pEGFP-N2 vector
(Invitrogen, Carlsbad, CA, USA), respectively, using EcoRI, XhoI sites. Cells were
transfected with 5mg of target gene expression vector or empty vector (EV) in
100-mm dishes using PolyFect Transfection Reagent (Qiagen) according to the
manufacturer’s instruction. After 60 days of screening, the cell lines stably
expressing B4GALT1 (HL60/B4GALT1), B4GALT5 (HL60/B4GALT5) and empty
vector (HL60/mock) were established. Then cells were collected for gene
expression assay and for further explorations.
In vitro drug cytotoxic assay. The CellTiter 96 AQueous One Solution
Cell Proliferation Assay (MTS) kit (Promega, Madison, WI, USA) was used to
determine the chemosensitivity of cell groups with genetic manipulation and
pharmacological inhibition of the Hh pathway. Cells (1 104) were seeded in
96-well plate and incubated with paclitaxel, vincristine and adriamycin (Sigma,
St. Louis, MO, USA) ,respectively, for 48 h. Then cells were stained with 10 ml
MTS for 3 h at 37 1C. The absorbance was measured at 490 nm by microplate
reader (Model 680; Bio-Rad, Hercules, CA, USA). The drug resistance was
estimated by comparing the IC50 values (drug concentration that inhibits cell
growth by 50%) from growth inhibition curves.
In vivo chemosensitivity assay. A total of 84 male nude mice (5 weeks
old) were acquired from the Animal Facility of Dalian Medical University and
equally divided into seven groups-HL60, HL60/ADR, HL60/ADR-control shRNA,
HL60/ADR-B4GALT1 shRNA, HL60/ADR-B4GALT5 shRNA, HL60/ADR-tomati-
dine and HL60/ADR-cyclopamine. Tumor cells (5 106) were injected into the
right flank of the nude mouse subcutaneously. Seven days later, tumors appeared
at the sites of injection, and then half of each group was randomly assigned to
receive 7 mg/kg adriamycin i.p. three times a week for 3 weeks, the rest tumor-
bearing mice of each group received normal saline injection as control. Twenty-
eight days after tumor implantation, IHC staining was conducted and external
caliper was used to determine the volume of xenografted tumors, and the tumor
volume was calculated by the following formula:
Tumor volume¼ 1/2(lengthwidth2)
IHC staining analysis. Visible tumors were removed from the mice and
immunohistochemistry was performed on paraffin-embedded sections. The slides
were dried, deparaffinized, rehydrated and then were immersed in 3% hydrogen
peroxide for 10 min to quench the endogenous peroxidase. After consecutive
washing with PBS, the slides were labeled overnight at 4 1C with anti-Shh, Smo,
GLI-1, B4GALT1 and T5 antibodies (Abcam) at a dilution of 1 : 200 or isotype
immunoglobulins (Santa Cruz Biotechnology) as negative control. The following
staining was performed at room temperature for 60 min with secondary streptavidin-
HRP-conjugated antibody (Santa Cruz Biotech). Finally, the sections were
counterstained with hematoxylin and cover-slipped. The Image-Pro Plus 4.5
Software (Media Cybernetics, Bethesda, MD, USA) was used to analyze the
expression of proteins.
Inhibition of the Hh signaling. Cyclopamine was used to suppress the
activity of the Hh signaling in HL60/ADR cells. Briefly, cells (1 104 cells per well)
were maintained in 100ml medium containing 0.5% FBS for 48 h in the presence
or absence of 6mM cyclopamine. Tomatidine, inactive but with similar structure to
cyclopamine, was served as control. Changes in chemosensitivity and gene
expression were measured by MTS assay and real-time PCR analysis,
respectively. Each experiment was run in triplicate to determine means and S.D.s.
Flow cytometry analysis. Tumor cells were washed with1PBS buffer
containing 20% bovine serum, and then were preincubated with 5% powdered
skim milk for 30 min to block nonspecific binding. For surface staining of P-gp and
MRP1, aliquots of cells were incubated with fluorescein isothiocyanate-anti human
P-gp, MRP1 (Abcam) or an isotype control antibody (Santa Cruz Biotech for
40 min at 4 1C at the recommended dilutions. After repeated centrifugation at
1000 r.p.m., labeled cells were resuspended in 0.2 ml PBS and were analyzed with
FACSCalibur (BD Biosciences, San Jose, CA, USA). Fluorescence intensity was
measured by Cell Quest software (BD Biosciences).
Statistical analysis. Statistical analysis was performed using SPSS17.0
statistical software (IBM Inc., Beijing, China). A one-way analysis of variance and
Student’s t-test was used to examine the possible differences in multiple
comparisons. Po0.05 was considered to be statistically significant. Each
experiment was repeated at least three times.
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Table 2 The primer sequences used for quantitative real-time PCR
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